XP-828L in the treatment of mild to moderate psoriasis: randomized, double-blind, placebo-controlled study.
BACKGROUND
XP-828L, a protein extract obtained from sweet whey, has demonstrated potential benefit for the treatment of mild to moderate psoriasis in an open-label study.


OBJECTIVE
To study in a randomized, double-blind, placebo-controlled study the safety and efficacy of XP-828L in the treatment of mild to moderate psoriasis.


METHODS
XP-828L 5 g/d (group A, n=42) or placebo (group B, n=42) was given orally for 56 days followed by XP-828L 5 g/d in group A and by XP-828L 10 g/d in group B for an additional 56 days.


RESULTS
Patients receiving XP-828L 5 g/d for 56 days had an improved Physician's Global Assessment (PGA) score compared with patients under placebo (p less than 0.05). Considering the data of group A only, the PGA score improved from day 1 to day 56 (p less than 0.01); the Psoriasis Area and Severity Index score improved as well, but to a lesser extent (p less than 0.05).


CONCLUSIONS
Oral administration of 5 g/d XP-828L compared with a placebo significantly improved the PGA score of patients with mild to moderate psoriasis.
Poulin
Yves
Y
Department of Medicine, Laval University, Quebec City, Quebec, Canada.
Bissonnette
Robert
R
Juneau
Christina
C
Cantin
Kim
K
Drouin
Rejean
R
Poubelle
Patrice E
PE
D000328:Adult; D000704:Analysis of Variance; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008894:Milk Proteins / Q000009:adverse effects / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D011792:Quebec; D012720:Severity of Illness Index
D003879:Dermatologic Agents; D008894:Milk Proteins; C518519:XP-828l